SCR-8079

SCR-8079 is a novel, selective, and orally bioavailable small molecule inhibitor of cyclin-dependent kinases 2, 4, and 6 (CDK2/4/6). Developed by Simcere Pharmaceutical Group, SCR-8079 is designed to overcome resistance to standard CDK4/6 inhibitors (such as palbociclib), which often arises due to CCNE1 gene amplification and subsequent abnormal activation of Cyclin E/CDK2. In preclinical studies, SCR-8079 demonstrated potent biochemical inhibition of CDK2, CDK4, and CDK6, with high selectivity over CDK1 and CDK9. It has shown robust anti-tumor activity in both CDK4/6-sensitive and resistant breast cancer cell lines, as well as in ovarian cancer models with elevated CDK2 activation.